Aldose reductase/polyol inhibitors for diabetic retinopathy

Irina G. Obrosova, Peter F Kador

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Diabetic retinopathy is the most common microvascular complication of diabetes and the most severe of diabetic ocular complications. This review describes retinal changes at different stages of diabetic retinopathy and risk factors associated with this devastating disease. Special attention is focused on aldose reductase, the first enzyme of the sor-bitol pathway of glucose metabolism. The current knowledge on the enzyme localization in the retina, and the role for increased aldose reductase activity in retinal capillary cell loss and formation of acellular capillaries, capillary basement membrane thickening, increased vascular permeability and disruption of blood-retinal barrier, and increased leukocyte adhesion to endothelial cells associated with early diabetic retinopathy, as well as neovascularization associated with advanced (proliferative) diabetic retinopathy, gained through the experimental studies in animal models of diabetes and ga-lactose feeding, is described in detail. The review also analyzes the potential mechanisms underlying aldose reductase involvement in pathogenesis of diabetic retinopathy, and discusses interactions between aldose reductase and other patho-genetic factors such as formation of advanced glycation end-products, oxidative-nitrosative stress, protein kinase C, mito-gen-activated protein kinase, and poly(ADP-ribose) polymerase activations, inflammation, and growth factor imbalances. A detailed analysis of clinical diabetic retinopathy trials of aldose reductase inhibitors is also provided.

Original languageEnglish (US)
Pages (from-to)373-385
Number of pages13
JournalCurrent Pharmaceutical Biotechnology
Volume12
Issue number3
DOIs
StatePublished - Feb 10 2011

Fingerprint

Aldehyde Reductase
Diabetic Retinopathy
Diabetes Complications
Blood-Retinal Barrier
Advanced Glycosylation End Products
Poly(ADP-ribose) Polymerases
Capillary Permeability
Enzymes
Lactose
Heat-Shock Proteins
Basement Membrane
Protein Kinases
Protein Kinase C
Retina
polyol
Intercellular Signaling Peptides and Proteins
Oxidative Stress
Leukocytes
Endothelial Cells
Animal Models

Keywords

  • Aldose reductase
  • Aldose reductase inhibitors
  • Diabetic retinopathy
  • Fidarestat
  • Pericyte loss
  • Retinopathy clinical trials
  • Sorbinil
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science

Cite this

Aldose reductase/polyol inhibitors for diabetic retinopathy. / Obrosova, Irina G.; Kador, Peter F.

In: Current Pharmaceutical Biotechnology, Vol. 12, No. 3, 10.02.2011, p. 373-385.

Research output: Contribution to journalArticle

@article{dbe80c443af54443bdea59944ddf3fc6,
title = "Aldose reductase/polyol inhibitors for diabetic retinopathy",
abstract = "Diabetic retinopathy is the most common microvascular complication of diabetes and the most severe of diabetic ocular complications. This review describes retinal changes at different stages of diabetic retinopathy and risk factors associated with this devastating disease. Special attention is focused on aldose reductase, the first enzyme of the sor-bitol pathway of glucose metabolism. The current knowledge on the enzyme localization in the retina, and the role for increased aldose reductase activity in retinal capillary cell loss and formation of acellular capillaries, capillary basement membrane thickening, increased vascular permeability and disruption of blood-retinal barrier, and increased leukocyte adhesion to endothelial cells associated with early diabetic retinopathy, as well as neovascularization associated with advanced (proliferative) diabetic retinopathy, gained through the experimental studies in animal models of diabetes and ga-lactose feeding, is described in detail. The review also analyzes the potential mechanisms underlying aldose reductase involvement in pathogenesis of diabetic retinopathy, and discusses interactions between aldose reductase and other patho-genetic factors such as formation of advanced glycation end-products, oxidative-nitrosative stress, protein kinase C, mito-gen-activated protein kinase, and poly(ADP-ribose) polymerase activations, inflammation, and growth factor imbalances. A detailed analysis of clinical diabetic retinopathy trials of aldose reductase inhibitors is also provided.",
keywords = "Aldose reductase, Aldose reductase inhibitors, Diabetic retinopathy, Fidarestat, Pericyte loss, Retinopathy clinical trials, Sorbinil, Vascular endothelial growth factor",
author = "Obrosova, {Irina G.} and Kador, {Peter F}",
year = "2011",
month = "2",
day = "10",
doi = "10.2174/138920111794480642",
language = "English (US)",
volume = "12",
pages = "373--385",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Aldose reductase/polyol inhibitors for diabetic retinopathy

AU - Obrosova, Irina G.

AU - Kador, Peter F

PY - 2011/2/10

Y1 - 2011/2/10

N2 - Diabetic retinopathy is the most common microvascular complication of diabetes and the most severe of diabetic ocular complications. This review describes retinal changes at different stages of diabetic retinopathy and risk factors associated with this devastating disease. Special attention is focused on aldose reductase, the first enzyme of the sor-bitol pathway of glucose metabolism. The current knowledge on the enzyme localization in the retina, and the role for increased aldose reductase activity in retinal capillary cell loss and formation of acellular capillaries, capillary basement membrane thickening, increased vascular permeability and disruption of blood-retinal barrier, and increased leukocyte adhesion to endothelial cells associated with early diabetic retinopathy, as well as neovascularization associated with advanced (proliferative) diabetic retinopathy, gained through the experimental studies in animal models of diabetes and ga-lactose feeding, is described in detail. The review also analyzes the potential mechanisms underlying aldose reductase involvement in pathogenesis of diabetic retinopathy, and discusses interactions between aldose reductase and other patho-genetic factors such as formation of advanced glycation end-products, oxidative-nitrosative stress, protein kinase C, mito-gen-activated protein kinase, and poly(ADP-ribose) polymerase activations, inflammation, and growth factor imbalances. A detailed analysis of clinical diabetic retinopathy trials of aldose reductase inhibitors is also provided.

AB - Diabetic retinopathy is the most common microvascular complication of diabetes and the most severe of diabetic ocular complications. This review describes retinal changes at different stages of diabetic retinopathy and risk factors associated with this devastating disease. Special attention is focused on aldose reductase, the first enzyme of the sor-bitol pathway of glucose metabolism. The current knowledge on the enzyme localization in the retina, and the role for increased aldose reductase activity in retinal capillary cell loss and formation of acellular capillaries, capillary basement membrane thickening, increased vascular permeability and disruption of blood-retinal barrier, and increased leukocyte adhesion to endothelial cells associated with early diabetic retinopathy, as well as neovascularization associated with advanced (proliferative) diabetic retinopathy, gained through the experimental studies in animal models of diabetes and ga-lactose feeding, is described in detail. The review also analyzes the potential mechanisms underlying aldose reductase involvement in pathogenesis of diabetic retinopathy, and discusses interactions between aldose reductase and other patho-genetic factors such as formation of advanced glycation end-products, oxidative-nitrosative stress, protein kinase C, mito-gen-activated protein kinase, and poly(ADP-ribose) polymerase activations, inflammation, and growth factor imbalances. A detailed analysis of clinical diabetic retinopathy trials of aldose reductase inhibitors is also provided.

KW - Aldose reductase

KW - Aldose reductase inhibitors

KW - Diabetic retinopathy

KW - Fidarestat

KW - Pericyte loss

KW - Retinopathy clinical trials

KW - Sorbinil

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=79551676547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551676547&partnerID=8YFLogxK

U2 - 10.2174/138920111794480642

DO - 10.2174/138920111794480642

M3 - Article

C2 - 20939801

AN - SCOPUS:79551676547

VL - 12

SP - 373

EP - 385

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 3

ER -